Exact Sciences Licenses OncoMethylome Biomarkers | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exact Sciences has licensed exclusive, worldwide rights from OncoMethylome Sciences to DNA methylation biomarkers for use in the stool-based detection of colorectal cancer.

In addition, Madison, Wis.-based Exact Sciences also licensed non-exclusive access to part of OncoMethylome's platform technology. In return, the Belgian firm will receive milestone payments and royalties on net sales

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CBC Marketplace commissions DNA testing of chicken sandwiches at Subway and other fast-food chains.

In a speech to Congress, President Donald Trump called the drug approval process at FDA "slow and burdensome."

In Genome Research this week: algorithm to tease out strains from metagenomic sequences, drug resistance mechanisms in cancer cells, and more.

Variants in the IFITM3 gene affect inflammatory response to infection, UPI reports.